

What is MeTA?

The Medicines Transparency Alliance (MeTA) is a DFID initiative that brings together public, private and civil society stakeholders with an interest in the outcomes of the medicines market to agree on through increased transparency in the supply chain. MeTA aims to increase transparency in the medicines market specifically in low- and middle-income countries, thereby strengthening healthcare governance and encouraging responsible business practice. MeTA is currently active in Ghana, Zambia, Uganda, Peru, Philippines, Jordan and Kyrgyzstan and is coordinated by a joint International MeTA Secretariat (IMS) based in the World Health Organization (WHO) and Health Action International (HAI).

Goal: To increase access to essential quality-assured medicines, especially for the poor and vulnerable through increased transparency in the pharmaceutical sector.

Mission: To contribute towards good governance, transparency and accountability, in procurement, management, supply, prescribing, dispensing and use of medicines in Jordan, through the engagement of all stakeholders with an interest in the outcome of the medicines market.

MeTA Jordan Pilot Phase

MeTA Jordan was launched as a pilot in March 2009, and was the first multi-stakeholder initiative aiming to improve access to medicines in the country. The initiative was spearheaded by the Ministry of Health, and led from the beginning by the High Health Council and for the first time brought together the government, the private sector and civil society to discuss the need for more information and greater transparency in the Jordanian medicines market. The pilot ended in 2010 and has been proven to work as both a catalyst for change and a driver of change.

Key successes in the Pilot Phase:

- The first forum in Jordan to bring all stakeholders in medicines together
- Increased engagement of civil society organizations (CSOs) in advocacy for access to medicines
- Improved Transparency in the selection of Essential Medicines
- Engagement with Rational Use and Standard Treatment Guidelines (STG)
- Multi-stakeholder National Drug Policy making

MeTA Phase 2

The activities of MeTA will support the government of Jordan to improve access to medicines in both the public as well as the private sector. In the preparation of the workplan, six expert committees have developed workplans in the following areas:

- **National Policies:** including NDP, Pricing, Rational Use of Medicines, STGs
- **Inefficiencies and cost containment in the Pharmaceutical Sector:** forecasting, supply chain management, STGs
- **Accountability in Public Sector Supply Chain:** RUM, STGs, code of ethics
- **Access and Equity:** availability, affordability, vulnerable groups and catastrophic diseases
- **Advocacy** with High Level policy makers using evidence base, routine disclosure and advocacy tools
- **Public Education** of quality assured generic medicine value, patient rights, communications
- **Monitoring & Evaluation:** total programme monitoring and transparency